Skip to content

Study · Randomized controlled trial · n = 10 · 2017

2 results

Low-Carbohydrate Diet Impairs the Effect of Glucagon in the Treatment of Insulin-Induced Mild Hypoglycemia: A Randomized Crossover Study.

Ranjan A, Schmidt S, Damm-Frydenberg C, Steineck I, Clausen TR, Holst JJ, Madsbad S, Nørgaard K

Diabetes care21 Oct 2016Cited by 53 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with type 1 diabetes, the first glucagon bolus raised glucose less after low- versus high-carbohydrate diet, 1.3 versus 2.7 mmol/L.

    In plain wordsIn patients with type 1 diabetes, glucagon raised glucose less after a low-carbohydrate diet than after a high-carbohydrate diet.

    Peptide
    Glucagon
    Outcome
    DecreaseGlucose rise after first glucagon bolus
    Study

    n = 10

    Comparator
    glucagon after high-carbohydrate diet
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    100 µg · subcutaneousAs given in this study (human).

    Measurements

    Incremental glucose rise
    1.3 mmol/L
    low-carbohydrate diet
    SEM
    0.3 mmol/L
    low-carbohydrate diet
    Incremental glucose rise
    2.7 mmol/L
    high-carbohydrate diet
    SEM
    0.4 mmol/L
    high-carbohydrate diet
    P value
    0.002
    diet comparison

    Source sentences

    Summary
    Compared with the HCD, the LCD resulted in lower incremental rises in PG after the first (mean ± SEM: 1.3 ± 0.3 vs. 2.7 ± 0.4 mmol/L, P = 0.002) and second glucagon bolus (4.1 ± 0.2 vs. 5.6 ± 0.5 mmol/L, P = 0.002).
    2 context sentences
    Summary · context
    Ten patients with insulin pump-treated type 1 diabetes randomly completed 1 week of the HCD (≥250 g/day) and 1 week of the LCD (≤50 g/day).
    Summary · context
    When PG reached 3.9 mmol/L, 100 µg glucagon was given subcutaneously, followed by 500 µg glucagon 2 h later.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with type 1 diabetes, the second glucagon bolus raised glucose less after low- versus high-carbohydrate diet, 4.1 versus 5.6 mmol/L.

    In plain wordsIn patients with type 1 diabetes, the second glucagon dose raised glucose less after a low-carbohydrate than a high-carbohydrate diet.

    Peptide
    Glucagon
    Outcome
    DecreaseGlucose rise after second glucagon bolus
    Study

    n = 10

    Comparator
    glucagon after high-carbohydrate diet
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    500 µg · subcutaneousAs given in this study (human).

    Measurements

    Incremental glucose rise
    4.1 mmol/L
    low-carbohydrate diet
    SEM
    0.2 mmol/L
    low-carbohydrate diet
    Incremental glucose rise
    5.6 mmol/L
    high-carbohydrate diet
    SEM
    0.5 mmol/L
    high-carbohydrate diet
    P value
    0.002
    diet comparison

    Source sentences

    Summary
    Compared with the HCD, the LCD resulted in lower incremental rises in PG after the first (mean ± SEM: 1.3 ± 0.3 vs. 2.7 ± 0.4 mmol/L, P = 0.002) and second glucagon bolus (4.1 ± 0.2 vs. 5.6 ± 0.5 mmol/L, P = 0.002).
    2 context sentences
    Summary · context
    Ten patients with insulin pump-treated type 1 diabetes randomly completed 1 week of the HCD (≥250 g/day) and 1 week of the LCD (≤50 g/day).
    Summary · context
    When PG reached 3.9 mmol/L, 100 µg glucagon was given subcutaneously, followed by 500 µg glucagon 2 h later.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT02578498

Glucagon Efficiency After High and Low Carbohydrate Diet

Hvidovre University Hospitaln = 10Oct 2015 to Jul 2016

Type 1 Diabetes · Hypoglycemia

Trial pageClinicalTrials.govUpdated 16 Aug 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.